Immediate Impact
49 standout
Citing Papers
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
2025 Standout
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
2025 Standout
Works of Junji Kawada being referenced
A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum: WJOG7112G (T-ACT).
2018
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Junji Kawada | 230 | 188 | 114 | 55 | 363 | |
| Guowei Kim | 153 | 285 | 62 | 39 | 381 | |
| Mustafa Duman | 118 | 216 | 113 | 69 | 372 | |
| Noel Salgado‐Nesme | 103 | 275 | 155 | 34 | 379 | |
| Naoki Shinno | 255 | 268 | 107 | 44 | 406 | |
| Micheal Tadros | 107 | 144 | 117 | 49 | 389 | |
| Leo Alexandre | 163 | 239 | 78 | 33 | 390 | |
| A Nakase | 134 | 243 | 185 | 41 | 412 | |
| Shuichi Takano | 141 | 158 | 77 | 54 | 378 | |
| Motonari Ri | 176 | 202 | 59 | 41 | 342 | |
| Yoshiyasu Kono | 201 | 212 | 64 | 57 | 361 |
All Works
Loading papers...